Biotechnology and genetic engineering in the new drug

Biotechnology and genetic engineering in the new drug

Pharmacological Reports
Copyright © 2013
2013, 65, 1086–1101
by Institute of Pharmacology
ISSN 1734-1140
Polish Academy of Sciences
Review
Biotechnology and genetic engineering
in the new drug development.
Part II. Monoclonal antibodies, modern vaccines
and gene therapy
Agnieszka Stryjewska1, Katarzyna Kiepura1, Tadeusz Librowski2,
Stanis³aw Lochyñski3
1
Department of Bioorganic Chemistry, Faculty of Chemistry, Wroc³aw University of Technology,
Wyb. Wyspiañskiego 27, PL 50-370 Wroc³aw, Poland
2
Department of Radioligands, Medical College, Faculty of Pharmacy, Jagiellonian University, Medyczna 9,
PL 30-688 Kraków, Poland
3
Institute of Cosmetology, Wroc³aw College of Physiotherapy, Koœciuszki 4, PL 50-038 Wroc³aw, Poland
Correspondence: Stanis³aw Lochyñski, e-mail: [email protected]; Tadeusz Librowski,
e-mail: [email protected]
Abstract:
Monoclonal antibodies, modern vaccines and gene therapy have become a major field in modern biotechnology, especially in the
area of human health and fascinating developments achieved in the past decades are impressive examples of an interdisciplinary interplay between medicine, biology and engineering. Among the classical products from cells one can find viral vaccines, monoclonal antibodies, and interferons, as well as recombinant therapeutic proteins. Gene therapy opens up challenging new areas.
In this review, a definitions of these processes are given and fields of application and products, as well as the future prospects, are
discussed.
Key words:
biotechnology, vaccines, traditional vaccines, modern vaccines, monoclonal antibodies, ziagen, thalidomide, alemtuzumab
1086
Pharmacological Reports, 2013, 65, 1086–1101